Curis, Inc. · NASDAQ:CRIS

Curis — Technical Presentation (2021)

9 slides from Curis's technical presentation, 2021

  1. Slide 1: The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma

    The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma Speaker: Christina A. von Roemeling, Ph.D.1 Research Team: Bently P. Doonan, M.D.1; Lan Hoang-Minh, Ph.D.1; Han W. Tun, M.D.2; Elizabeth Martinez, Ph.D.3, Raul Soikes, M.S.3; Reinhard W. von Roemeling,

  2. Slide 2: Speaker disclosures

    Speaker: Christina von Roemeling Duane Mitchell received institutional funds from Curis, Inc. Reinhard von Roemeling, Elizabeth Martinez, and Raul Soikes are employees of Curis, Inc.

  3. Slide 3: CA-4948 is a novel small molecule inhibitor of IRAK4

    CA-4948 is a novel small molecule inhibitor of IRAK4 CA-4948 Adapted from Booher, et al. AACR Annual Meeting (2017)

  4. Slide 4: IRAK signaling is activated in PCNSL

    IRAK signaling is activated in PCNSL

  5. Slide 5: CA-4948 can cross the blood brain barrier

    CA-4948 can cross the blood brain barrier CA-4948 Conc. (ug/mL or ug/G) 100 Plasma CSF 10 Brain (naive) Brain (A20 tumor) 1 NFΚB EC50 0.1 0.01 0 2 4 6 8 Time (H)

  6. Slide 6: CA-4948 reduces MAPK expression in preclinical PCNSL

    CA-4948 reduces MAPK expression in preclinical PCNSL p-P38 BV DAPI p-ERK1/2 BV DAPI % pERK1/2Thr202/Tyr204 positivity p=0.005 p=0.018 15 % pP38Thr180/Tyr182 positivity 60 10 40 5 20 0 0 e 8 cl 94 e 8 hi cl 94 -4 Ve hi A -4 Ve C A C

  7. Slide 7: CA-4948 reduces NF-κB expression in preclinical PCNSL

    CA-4948 reduces NF-κB expression in preclinical PCNSL p=0.027 2500 2000 pP65Ser536 MFI 1500 1000 500 0 e 8 cl 94 hi -4 Ve A C

  8. Slide 8: CA-4948 improves survival in preclinical PCNSL

    CA-4948 improves survival in preclinical PCNSL 100 CA-4948 Med. Survival % survival (A20: CNS-BCL) excipient 26 days 80 50 mg/kg 30.5 days 100 mg/kg 42 days 60 40 20 0 0 20 40 60 80 Time (Days)

  9. Slide 9: Contact Information

    Contact Information: Christina A. von Roemeling: [email protected] Raul Soikes: [email protected]

Curis — Technical Presentation (2021) on 6ix